// App-Quantinova.ai

P653 : OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL-WORLD STUDY OF A LARGE U.S. DATABASE

Researchers

Presenter

  • Toby A Eyre

Principal Investigators

  • Lisa Hess

  • Tomoko Sugihara

  • Richard A Walgren

  • Paolo B Abada

  • Heiko Konig

  • John Pagel

  • Lindsey E Roeker

  • Anthony Mato

Medical Centers

  • Syneos Health,Austin,États-unis

  • Loxo Oncology at Lilly,Stamford, CT,United St

  • Syneos Health,Austin,Vereinigte Staaten

  • Elli Lily and Company ,Indianapolis,Estados Unidos

  • Elli Lily and Company,Indianapolis,Vereinigte Staaten

  • Elli Lily and Company,Indianapolis,Vereinigte Staaten

  • Loxo Oncology,Stamford,Verenigde Staten

  • Syneos Health,Austin,USA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Syneos Health,Austin,Vereinigte Staaten

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Memorial Sloan Kettering Cancer Center,New York ,États-unis

  • Elli Lily and Company ,Indianapolis,Estados Unidos

  • Syneos Health,Austin,Estados Unidos

  • Eli Lilly and Company Indianapolis IN United States

  • Syneos Health,Austin,Stati Uniti

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Memorial Sloan Kettering, NY

  • Syneos Health,Austin,United States

  • Loxo Oncology,Stamford,Vereinigte Staaten

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Oxford University Hospitals, NHS Foundati

  • Oxford University Hospitals NHS Foundation Trust Oxford UK

  • Oxford University Hospitals NHS Trust,Oxford,Vereinigtes Königreich

  • Eli

  • Oxford University Hospitals NHS Foundation Trust Oxford UK

  • Elli Lily and Company ,Indianapolis,Estados Unidos

  • Loxo Oncology, Stamford, CT

  • Oxford University Hospitals NHS Foundation Trust Oxford UK

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • B-cell lymphoma 2

  • Bruton tyrosine kinase

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved